OCON Therapeutics

The Modiin, Israel-based company's business model revolves around the innovation, manufacturing, and commercialization of products built on its IUB™ platform. Revenue is generated through the sale of its devices to healthcare providers and distributors in the FemTech and women's health markets. OCON's first commercial product is the IUB™ Ballerine®, a CE-approved, hormone-free copper contraceptive effective for up to five years. This product is distinguished by its spherical shape, which is designed for a more comfortable fit within the uterine cavity, aiming for a less painful insertion and a reduction in complications. The IUB™ Ballerine® is commercially available in 30 countries and has been used by over 150,000 women.

Beyond contraception, OCON is leveraging the IUB™ frame as a versatile drug delivery system. A key product in its pipeline is the IUB™ SEAD®, a disposable, point-of-care therapy for Abnormal Uterine Bleeding (AUB) and Heavy Menstrual Bleeding (HMB). Positioned as a less invasive and more cost-effective alternative to surgical procedures like endometrial ablation, the IUB™ SEAD® has completed Phase IIb clinical studies and the company is preparing for pivotal studies in the USA. The pipeline also includes the IUB™ PRIMA for heavy bleeding, IUB™ STELLA for endometriosis, and IUB™ ADIRA for uterine fibroids, targeting a market where conditions affect up to 80% of women. The company has raised approximately $40 million in total funding from investors including RH Capital, Pontifax VC, and Astia Angels, and is preparing for a Series A round to expand its product pipeline.